Table 5. Five-year relative survival of female patients from Saarland with invasive breast cancer (ICD-10 code: C50) by hormone receptor status and stratified by age and stage estimated for the calendar period 2005-2009 based on completed datasets.
| Hormone receptor status | overall |
age |
stage |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
15-69 years |
70+ years |
localized |
locally/regionally advanced |
distant metastasis |
||||||||
| RSa | SE | RS | SE | RS | SE | RSa | SE | RSa | SE | RSa | SE | ||
| positive (ER+ PgR+) | 87.7 | 1.0 | 92.8 | 0.7 | 81.2 | 2.2 | 99.3 | 1.5 | 86.0 | 1.7 | 29.8 | 3.5 | |
| mixed (ER+ or PgR+) | 81.8 | 2.6 | 86.0 | 2.2 | 75.4 | 5.2 | 101.3 | 3.5 | 74.1 | 4.4 | 16.3 | 7.3 | |
| negative (ER-PgR-) | 65.3 | 2.4 | 73.4 | 2.1 | 55.8 | 5.0 | 86.7 | 4.4 | 57.7 | 4.3 | 8.2 | 3.6 | |
NB: RS = point estimate of 5-year relative survival; SE = standard error of RS; ER: estrogen receptor; PgR: progesterone receptor; a age standardized estimates were derived using the ICSS weights; cases without microscopic verification were excluded; the survival estimates were derived from 10 completed datasets using multiple imputation